Cohort Profile

Virus Watch - understanding community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviour

Byrne, Thomas; Kovar, Jana; Beale, Sarah; Braithwaite, Isobel; Fragaszy, Ellen; Fong, Wing Lam Erica; Geismar, Cyril; Hoskins, Susan; Navaratnam, Annalan M.D.; Nguyen, Vincent; Patel, Parth; Shrotri, Madhumita; Yavlinsky, Alexei; Hardelid, Pia; Wijlaars, Linda; Nastouli, Eleni; Spyer, Moira; Aryee, Anna; Cox, Ingemar; Lampos, Vasileios; McKendry, Rachel A.; Cheng, Tao; Johnson, Anne M.; Michie, Susan; Gibbs, Jo; Gilson, Richard; Rodger, Alison; Abubakar, Ibrahim; Hayward, Andrew; Aldridge, Robert W.

Published in:
International Journal of Epidemiology

DOI:
10.1093/ije/dyad087

Publication date:
2023

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):

Download date: 13. jul., 2024
Cohort Profile

Cohort Profile: Virus Watch—understanding community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviour

Thomas Byrne,1,† Jana Kovar,1,‡ Sarah Beale,1,2 Isobel Braithwaite,1 Ellen Fragasy,2,3 Wing Lam Erica Fong,1 Cyril Geismar,1,4 Susan Hoskins,2 Annalan MD Navaratnam,1,2 Vincent Nguyen,1,2 Parth Patel,1 Madhumita Shrotri,1 Alexei Yavlinsky,1 Pia Hardelid,5 Linda Wijlaars,5 Eleni Nastouli,5,6,7 Moira Spery,6 Anna Aryee,1 Ingemar Cox,8 Vasileios Lampos,8 Rachel A Mckendry,9 Tao Cheng,10 Anne M Johnson,11 Susan Michie,12 Jo Gibbs,13 Richard Gilson,13 Alison Rodger,13,14 Ibrahim Abubakar,15 Andrew Hayward,2,† and Robert W Aldridge1,*,‡

1Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK, 2Institute of Epidemiology and Health Care, University College London, London, UK, 3Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK, 4MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK, 5Department of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, University College London, London, UK, 6Francis Crick Institute, London, UK, 7University College London Hospital, London, UK, 8Department of Computer Science, University College London, London, UK, 9London Centre for Nanotechnology and Division of Medicine, University College London, London, UK, 10SpaceTimeLab, Department of Civil, Environmental and Geomatic Engineering, University College London, London, UK, 11Centre for Population Research in Sexual Health and HIV, Institute for Global Health, London, UK, 12Centre for Behaviour Change, University College London, London, UK, 13Institute for Global Health, University College London, London, UK and 14Royal Free London NHS Foundation Trust, London, UK

*Corresponding author. Centre for Public Health Data Science, Institute of Health Informatics, University College London, London NW1 2DA, UK. E-mail: r.aldridge@ucl.ac.uk
†Joint first authors.
‡Joint senior authors.

Received 22 December 2022; Editorial decision 1 May 2023; Accepted 31 May 2023
Why was the cohort set up?

The United Kingdom Research and Innovation (UKRI) Medical Research Council (MRC) and the Department of Health and Social Care National Institute for Health and Care Research (DHSC NIHR) funded Virus Watch in April 2020 under the COVID-19 Rapid Response Call 2. During the early stage of the pandemic in the UK, (February/March 2020), data on COVID-19 were largely collected in hospital settings. Our aim was to bring together an experienced team of respiratory infectious disease epidemiologists to rapidly establish a national community cohort study of COVID-19 in households living in England and Wales which built upon our experience from Flu Watch—a community cohort designed to estimate community burden of influenza and influenza-like illness.1 The DHSC/UKRI awarded additional funding to the study (under the Rapid Response Initiative call) in August 2020 to recruit larger numbers of minority ethnic and migrant populations when it became increasingly apparent that these groups were under-represented in research studies although experiencing greater risk of hospitalization and death from COVID-19.

Virus Watch aims to provide evidence on which public health approaches are most likely to be effective in reducing the spread and impact of the virus and investigates community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviour.2

The main research questions we set out to address were: what is the rate of infection; what is the rate of infected people experiencing symptoms; what is the rate of people seeking health care; what are the hospitalization and mortality rates associated with COVID-19, at different points in time and within different population groups. We wanted to describe COVID-19 symptoms and their severity and to understand people’s behaviour in terms of infection prevention as well as movement, travel, activities and social contact. Understanding how these outcomes differ by ethnicity, migration and deprivation, and what risk factors may explain any differences, constituted some of our key objectives.

In addition, we wanted to understand how negative consequences of the COVID-19 pandemic and public health control measures affect economic circumstances and mental health. We had a particular focus on people from minority ethnic and migrant backgrounds and how access to primary care for COVID-19 varied among these groups compared with the White British population, and what factors might explain this.

After vaccines became available in the UK in December 2020, further funding was provided by the DHSC for undertaking serological testing for a subset of the Virus Watch cohort. This programme ran from February 2021 to April 2022, and was designed to assess the effectiveness and impact of COVID-19 vaccines on both symptomatic and asymptomatic infections and on transmission. We wanted to compare the effectiveness of vaccines in different population subgroups and to assess the duration of protection, correlates of protection and immunity against emerging strains.

Who is in the cohort?

As of March 2022, 58 628 participants aged 0–98 years (mean age 48 years) from 28 527 households had enrolled...
Households living in England and Wales self-selected into the study, and all members of a household had to consent to take part. Households were required to have either a mobile telephone, tablet or computer with an internet connection, a valid email address and at least one household member who could read and respond in English to complete regular surveys. Household size ranged from one person to a maximum of six (see Supplementary Table S1, available as Supplementary data at IJE online). This criterion was set due to limitations of the REDCap survey infrastructure used.

Virus Watch is a prospective, household, community cohort study. Recruitment methodology was adapted throughout the study (see Supplementary Table S2, available as Supplementary data at IJE online) to ensure the target number of participants from the general population was reached. We also aimed to recruit a sufficiently large sample of participants from minority ethnic backgrounds to investigate infection risk and impact of the pandemic on specific groups of interest. Postcards, leaflets and adverts used to recruit participants were designed to inform individuals about the study and direct them to our website [http://ucl-virus-watch.net/] where they could self-select into the study.

We worked with nine of the 15 NIHR Local Clinical Research Networks (LCRN) across England to send SMS messages from general practitioner (GP) clinics to their patient lists, with a link to the study website inviting participants to take part. To boost recruitment of minority ethnic participants into the cohort, we sent targeted letters based on ethnicity via 90 GP clinics from nine LCRNs which included a £20 voucher incentive per household to sign up. Digital invitations were shared via trusted networks including patient advocacy group websites, Twitter, Facebook and WhatsApp. We also undertook a paid advertising campaign via Facebook. Study participants were emailed and asked to share an invite with their family and friends. Throughout the pandemic, multiple newspaper articles, radio and TV appearances of the study team also contributed to public-facing exposure and recruitment. The cumulative total of participants recruited by method of recruitment is provided in Figure 1.

In total, 79 clinics across England and Wales took part in the laboratory subcohort, with each site determining a target sample size for blood-taking according to staff capacity. To reach this target, a random selection of all Virus Watch (see Table 1). Households living in England and Wales self-selected into the study, and all members of a household had to consent to take part. Households were required to have either a mobile telephone, tablet or computer with an internet connection, a valid email address and at least one household member who could read and respond in English to complete regular surveys. Household size ranged from one person to a maximum of six (see Supplementary Table S1, available as Supplementary data at IJE online). This criterion was set due to limitations of the REDCap survey infrastructure used.
Watch households within a 5-km (urban areas) or 10-km radius (rural areas) around each site were invited to come into the clinic to provide a whole-blood sample for serological testing. The recruitment rate into the laboratory subcohort was 65%, with 6302 households of 12,878 individuals invited to take part, and 4096 households and 6947 participants providing at least one sample.

Eligible households for the vaccination subcohort were defined as having at least one adult aged 18 years and over, a valid England or Wales postcode, a complete postal address registered at enrolment, complete gender and ethnicity information for all household members, and not enrolled in the laboratory subcohort. We invited adults (aged 18+ years) from 20,490 households to take part and a total of 14,554 agreed (response rate 71%). The participation rate was high, with a total of 107,708 samples collected from 19,556 individuals during the study (see Supplementary Table S3, available as Supplementary data at IJE online for the number of follow-up samples collected by individual).

Between September 2020 and February 2021, we invited 13,120 adults (aged 18+ on entry) from the Virus Watch study to contribute geolocation data for a period up to 12 months; 2193 individuals (16%) agreed to take part and individuals were free to opt out at any time.

Several demographic groups are under-represented in the study. The cohort is older (mean age = 48 years), with a greater proportion of people in the 45–64-year age group when compared with the general population. Some ethnic groups are also under-represented, notably the Black and Other Asian groups (Table 1). Our ability to disaggregate data into more granular categories of ethnicity is limited due to the small number of people in these groups enrolled in the study.

How often have the participants been followed up?

After signing up to the study and completing a baseline survey for every member of the household, a nominated household study lead completed a weekly online illness survey and occasional surveys (from December 2020) about pandemic-relevant sociodemographic and clinical factors.

Participants in the laboratory subcohort were invited to either attend a clinic in their local area or schedule a home visit to have their blood taken on two occasions (Oct 2020 to Jan 2021 and again between May and August 2021). Participants who were unable to visit a clinic and could not receive a home visit were asked to provide a finger prick sample (in clinic or self-collected at home). Between October 2020 and May 2021, participants also posted self-administered nasal swabs for polymerase chain reaction (PCR) assays of SARS-CoV-2 if they experienced any of...
the following symptoms for 2 or more days: fever, cough or loss or change of sense of taste or smell. The design of the laboratory subcohort, including the sample collection algorithm and specific symptoms of interest, has been published in the study protocol.²

Adults taking part in the vaccine evaluation subcohort posted self-collected finger prick capillary blood microsamples monthly between February and August 2021, and every other month from September 2021 to March 2022.

For participants living in England, linkage of Virus Watch to data held by NHS Digital (Hospital Episode Statistics, Death Registrations, National Immunisation Management System (NIMS), COVID Vaccine Adverse Events Data, virological surveillance data) will take place quarterly during the study and for up to 5 years after the end of the study (until 30 September 2026).

Retention of participants in the study has decreased over time. Many participants dropped out of the study and failed to complete any weekly surveys after enrolling but, among those who completed at least one weekly survey, engagement was high. In the first 6 months of the study, approximately 75% of enrolled participants were regularly completing the weekly illness surveys (Figure 2). Over the course of the pandemic, the proportion of participants who were lost to follow-up steadily increased and by March 2022, the proportion still regularly completing surveys had reduced to around 50% of enrolled participants. Participants self-select into the study and are free to stop participating at any time. We used a 75% survey completion rate for weekly surveys as a cut-off to compare the characteristics of high responders and low responders. Participants who completed less than 75% of all possible weekly surveys were more likely to be younger, from an ethnic minority background and living in London (Table 2).

Missing demographics from the baseline survey were requested via a short one-off survey of 5312 study households (n = 14 166 participants) in February 2021. This provided 857 (16%) household addresses, the sex of 3985 (28%) people and the ethnicity of 3819 (27%) people.

For records with missing sex data after linkage to NHS Digital data, we assigned gender using the probability of given names being male or female based on US names from 1930 to 2015 [https://data.world/howarder/gender-by-name].⁵ Sex was reported by 49 255 participants, and following gender matching by name, a further 8552 classifications of sex were inferred. The accuracy of this technique was tested on the 49 255 complete records and found to be 99.82%. Notably, this method fails to account for the minority of individuals who are intersex/other non-binary gender identities and should be interpreted with this in mind.

Data linkage to NIMS for immunization records up to 23 December 2021 yielded an additional 11 221 records for Dose 1 of COVID-19 vaccine which were not self-reported, 12 593 for Dose 2, 14 009 for Dose 3, 41 for Dose 4 and 12 for Dose 5. We anticipate future data linkage to increase the number of matched missing records for Doses 4 and 5. Linkage to the ONS mortality dataset held by NHS Digital, identified 153 participants who had died.

Figure 2 Count of survey completions by week since the start of Virus Watch recruitment (June 2020 to March 2022) showing recruitment (total number of participants who completed at least one survey) and retention (total number of participants who completed the latest survey for a given week).
(up to November 2021) compared with 59 reported deaths by household or family members.

Study participant data were linked to the national ‘Pillar 2’ COVID-19 community testing programme by NHS Digital, which provided an additional 291,067 test results (negative and positive results). We asked participants to self-report only positive test results and the first subsequent negative result via the weekly surveys; consequently only one result was recorded per week per participant. This likely explains the difference between the high number of tests recorded via Pillar 2 compared with our study. Linking to the Second Generation Surveillance System (SGSS), which contains results of testing performed in hospital patients and health and care workers and is held by NHS Digital, provided 5,345 additional test results.

What has been measured?

Participants completed detailed study questionnaires online via REDCap database tools hosted on the secure University College London (UCL) Data Safe Haven. Demographic, clinical and socioeconomic data were collected at baseline for each household member, as well as

Table 2 Cohort characteristics stratified by proportion of possible surveys completed (less than 75% versus greater than or equal to 75% of surveys completed)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>≥75% of surveys completed (n=24,915)</th>
<th>&lt;75% of surveys completed (n=33,713)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age group (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–15</td>
<td>1512 (6.1%)</td>
<td>5,859 (17%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>16–24</td>
<td>828 (3.3%)</td>
<td>2,671 (7.9%)</td>
<td></td>
</tr>
<tr>
<td>25–44</td>
<td>2,357 (9.5%)</td>
<td>9,368 (28%)</td>
<td></td>
</tr>
<tr>
<td>45–64</td>
<td>9,201 (37%)</td>
<td>10,456 (31%)</td>
<td></td>
</tr>
<tr>
<td>65+</td>
<td>11,017 (44%)</td>
<td>5,359 (16%)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male</td>
<td>11,095 (45%)</td>
<td>15,179 (45%)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>13,775 (55%)</td>
<td>17,758 (53%)</td>
<td></td>
</tr>
<tr>
<td>Missing/prefer not to say</td>
<td>45 (0.2%)</td>
<td>776 (2.3%)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>White British</td>
<td>21,735 (87%)</td>
<td>18,746 (56%)</td>
<td></td>
</tr>
<tr>
<td>White Irish</td>
<td>330 (1.3%)</td>
<td>341 (1.0%)</td>
<td></td>
</tr>
<tr>
<td>White other</td>
<td>1,098 (4.4%)</td>
<td>1,718 (5.1%)</td>
<td></td>
</tr>
<tr>
<td>Mixed</td>
<td>312 (1.3%)</td>
<td>686 (2.0%)</td>
<td></td>
</tr>
<tr>
<td>South Asian</td>
<td>490 (2.0%)</td>
<td>2,238 (6.6%)</td>
<td></td>
</tr>
<tr>
<td>Other Asian</td>
<td>155 (0.6%)</td>
<td>272 (0.8%)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>116 (0.5%)</td>
<td>377 (1.1%)</td>
<td></td>
</tr>
<tr>
<td>Other ethnicity</td>
<td>84 (0.3%)</td>
<td>204 (0.6%)</td>
<td></td>
</tr>
<tr>
<td>Prefer not to say</td>
<td>53 (0.2%)</td>
<td>139 (0.4%)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>542 (2.2%)</td>
<td>8,992 (27%)</td>
<td></td>
</tr>
<tr>
<td>Region</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>North East</td>
<td>1,217 (4.9%)</td>
<td>1,311 (3.9%)</td>
<td></td>
</tr>
<tr>
<td>North West</td>
<td>2,660 (11%)</td>
<td>2,912 (8.6%)</td>
<td></td>
</tr>
<tr>
<td>Yorkshire and the Humber</td>
<td>1,353 (5.4%)</td>
<td>1,682 (5.0%)</td>
<td></td>
</tr>
<tr>
<td>East Midlands</td>
<td>2,346 (9.4%)</td>
<td>2,599 (7.7%)</td>
<td></td>
</tr>
<tr>
<td>West Midlands</td>
<td>1,481 (5.9%)</td>
<td>1,539 (4.6%)</td>
<td></td>
</tr>
<tr>
<td>East of England</td>
<td>5,042 (20%)</td>
<td>5,503 (16%)</td>
<td></td>
</tr>
<tr>
<td>London</td>
<td>2,878 (12%)</td>
<td>6,205 (18%)</td>
<td></td>
</tr>
<tr>
<td>South East</td>
<td>4,767 (19%)</td>
<td>5,078 (15%)</td>
<td></td>
</tr>
<tr>
<td>South West</td>
<td>2,052 (8.2%)</td>
<td>1,904 (5.6%)</td>
<td></td>
</tr>
<tr>
<td>Wales</td>
<td>687 (2.8%)</td>
<td>845 (2.5%)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>432 (1.7%)</td>
<td>4,135 (12%)</td>
<td></td>
</tr>
</tbody>
</table>

*Pearson’s chi-squared test.

Sex at birth was self-reported. If missing, sex was obtained via linkage to HES or via name-gender matching based on US names from 1930 to 2015 (https://data.world/howarder/gender-by-name).
any previous COVID-19 illness. Participants self-reported comorbidities from a detailed list and, in subsequent analyses, we created two clinically vulnerable variables. Clinically extremely vulnerable participants were defined using criteria set out by Public Health England and the Department of Health and Social Care as part of the guidance for shielding. Individuals were categorized as clinically vulnerable using criteria set out by the Joint Committee on Vaccination and Immunisation.

Symptoms, activities, COVID-19 test results and vaccinations were reported in repeat weekly illness surveys. Occasional surveys asked questions on a broad range of topics including behaviours, mental health and disability. The occasional surveys were varied in scope and format and were flexibly tailored to the pandemic phase. Table 3 summarizes the survey data collected from Virus Watch participants, additional data acquired from linkage via NHS Digital, biological data collected from participants in the laboratory and vaccine efficacy subcohorts, and geolocation data from an optional movement tracker app sub-study. This app (ArcGIS Tracker), downloaded by individual participants (the whole household was not required to take part) onto their mobile devices.

Table 3 Summary of data items collected from Virus Watch participants, including data source, type of data and top-level categories of variables included

<table>
<thead>
<tr>
<th>Data source</th>
<th>Data type</th>
<th>Variable categories</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration survey</td>
<td>Demographic</td>
<td>Name, date of birth, address, GP address, NHS number, mobile number, email</td>
</tr>
<tr>
<td>Baseline survey</td>
<td>Demographic</td>
<td>Sex, country of birth, date of arrival into the UK, ethnicity</td>
</tr>
<tr>
<td></td>
<td>Clinical</td>
<td>Medications, comorbidities, height, weight, flu vaccination, alcohol and tobacco use, European Quality of Life 5 Dimensions 3 Level Version (EQ5-5D-3L)</td>
</tr>
<tr>
<td></td>
<td>Socioeconomic</td>
<td>Employment status, occupation, health or social care worker status, working from home, travel to work, household income, household finances, childcare and/or caring responsibilities (derived from postcode Lower-layer Super Output Area-level Indices of Multiple Deprivation)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical extremely vulnerable participants were defined using criteria set out by Public Health England and the Department of Health and Social Care as part of the guidance for shielding. Individuals were categorized as clinically vulnerable using criteria set out by the Joint Committee on Vaccination and Immunisation.</td>
</tr>
<tr>
<td>Weekly follow-up survey</td>
<td>Symptoms</td>
<td>Type of symptoms (general, respiratory, gastrointestinal etc), list of symptoms (including fever, cough, loss or change in sense of smell etc), date of symptom onset and duration, severity</td>
</tr>
<tr>
<td></td>
<td>Activities</td>
<td>Close contacts, self-isolation, face mask wearing, leaving the house, meeting others in a bar/pub/party, using public transport, going shopping, attending work/education, going to a place of worship</td>
</tr>
<tr>
<td></td>
<td>COVID-19 infection</td>
<td>COVID-19 PCR or lateral flow test results, date of test, date of result, requests to self-isolate</td>
</tr>
<tr>
<td></td>
<td>COVID-19 vaccination</td>
<td>Date of vaccination, dose, vaccine type, participation in vaccine trial</td>
</tr>
<tr>
<td>Occasional survey</td>
<td>Clinical, demographic,</td>
<td>Contact patterns and public activities, views on vaccination, long COVID, social distancing and isolation, housing, everyday discrimination, mental health (Patient Health Questionnaire [PHQ-9] and Generalised Anxiety Disorder Assessment [GAD-7] to assess depression and anxiety), health conditions and medications, lateral flow testing, behaviour after vaccination, access to healthcare, financial impacts of the pandemic, disability</td>
</tr>
<tr>
<td></td>
<td>COVID-19 infection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>COVID-19 vaccination</td>
<td>Date of vaccination, dose, vaccine type, participation in vaccine trial</td>
</tr>
<tr>
<td></td>
<td>Administrative data</td>
<td>HES (Admitted Patient Care, Outpatient Bookings, Emergency Care Dataset and Critical Care), ONS mortality data, NIMS, Pillar 2 and SGSS</td>
</tr>
<tr>
<td>Data linkage</td>
<td>Geolocation data</td>
<td>Longitude, latitude, horizontal accuracy, vertical accuracy, speed, travel mode, date and time</td>
</tr>
<tr>
<td>ArcGIS tracker</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory subcohort</td>
<td>COVID-19 laboratory test results</td>
<td>PCR positive or negative, blood serum tested for spike and nucleocapsid antibody—positive or negative</td>
</tr>
<tr>
<td>Vaccine efficacy subcohort</td>
<td>Quantitative antibody levels</td>
<td>Spike and nucleocapsid levels</td>
</tr>
<tr>
<td></td>
<td>Neutralisation assay on breakthrough infections</td>
<td>Variants tested depended on circulating strains in the UK</td>
</tr>
</tbody>
</table>

GP, General Practice; HES = Hospital Episode Statistics; NHS = National Health Service; PCR = polymerase chain reaction; SGSS = Second Generation Surveillance System; UK = United Kingdom.

aFor participants living in England only.
bAdults and children.
cAdults (aged 18 years and over) only.
phones, measured longitude, latitude, date, time, travel mode and GPS accuracy which was defined by the phone manufacturer’s GPS algorithm for up to 12 months.

As of 7 December 2022, 1,619,300 weekly surveys had been submitted with 21,299,348 person-days of follow-up. In total, 351,751 individual responses to occasional surveys were received and 190,993,995 GPS coordinates. From laboratory subcohorts, we collected 10,974 full serological samples, 107,708 finger-prick samples and, of these, 4,972 live virus neutralization activity of capillary microsamples were tested.

What have we found?

Virus Watch aimed to provide evidence on the transmission and impact of COVID-19 and to estimate key epidemiological measures including: the incidence of PCR-confirmed COVID-19; incidence of hospitalization among PCR-confirmed COVID-19 cases; incidence of respiratory infection symptoms, including COVID-19 disease case definitions; and secondary household attack rates. Other outcomes of interest included investigating the effectiveness and impact of control measures including testing, isolation, social distancing and vaccine effectiveness against asymptomatic and symptomatic infections.

Early in the pandemic, we took an active decision to avoid duplication of effort in reporting the incidence of infection and hospitalization once the ONS COVID-19 Infection Survey and the UK Health Security Agency dashboard data were established, and chose to focus on investigating: the symptoms of COVID-19 and COVID-19-like illness; risk factors for, and behaviours associated with, infections and vaccination; and immunity against COVID-19. We have published a summary of key findings on the study website [https://ucl-virus-watch.net/?page_id=1323] and a full list of publications and pre-prints is available at [https://ucl-virus-watch.net/?page_id=1388].

The more deprived communities have been disproportionately affected by the health, social and economic effects of the COVID-19 pandemic. Greater day-to-day exposure to people outside their household and/or support bubble (e.g. lesser ability to work from home, greater dependence on public transport etc.) may be driving higher infections, hospitalizations and deaths in deprived areas. To explore this we used participant-reported data on daily activities during three weekly periods in late November 2020, late December 2020 and mid-February 2022.10 During the final week of November and the December holiday period (23–27 December 2020), participants living in more deprived areas were more likely to: leave their house to go to work or school; use public transport; share a car with a non-household member; visit an essential shop; and have close contact with a non-household/support bubble member than participants living in the least deprived areas. Participants living in more deprived areas were not more likely to undertake social and entertainment activities or visit non-essential shops and services. Our findings suggest that differences in essential daily activities are likely to be contributing to higher infection rates in more deprived regions. These differences are likely to reflect circumstances that constrain individual choice, e.g. car ownership, ability to work from home and disposable income. There was no observed difference in activities that are more likely to reflect individual decision making, such as attending non-essential shops or social and entertainment activities.

Work investigating anti-spike (S) SARS-CoV-2 antibody levels among Virus Watch participants who had received COVID-19 vaccines provided key insights into antibody waning and protection against breakthrough infections.7,11–13 In one analysis following the vaccine roll-out in the UK, we measured antibody levels in almost 9000 study participants who had received two doses of ChAdOx-S1 or BNT162b2 vaccine at 3 weeks after the second dose and 20 weeks after the second dose, respectively.7 Antibody levels dropped at the same rate for both vaccines, but peak levels were much higher following the BNT162b2 vaccine. We found those with lower antibody levels were at increased risk of infection. We also showed that peak anti-S levels are higher post-booster than post-second dose, but that levels are projected to be similar after 6 months for BNT162b2 recipients. Whereas peak antibody levels post-second dose were substantially lower for ChAdOx-S1 than BNT162b2 recipients, no differences in post-booster antibody levels by primary course type were observed (Supplementary Figure S1, available as Supplementary data at IJE online). The magnitude and trajectory of post-booster anti-S response was similar across age groups and by clinical vulnerability status. Higher peak anti-S levels post-booster may partially explain the increased effectiveness of booster vaccination compared with two-dose vaccination against symptomatic infection with the Omicron variant.

What are the main strengths and weaknesses?

Following up whole households longitudinally, rather than being limited to individuals, is a unique strength of Virus Watch. The cohort has data on all ages including children and adolescents, and is broadly representative of the UK population on geographical spread and deprivation (Table 1), with some exceptions. A particular focus was placed on engaging participants from minority ethnic groups, with recruitment methods and research question prioritization being guided by our study advisory group composed of community
leaders, policy experts and charity representatives. Study sur-
veys and data collection methodologies were developed based
upon 6 years of experience running large national surveillance
cohorts of pandemic and seasonal influenza,14 and we used
validated questionnaires wherever feasible (e.g. Patient
Health Questionnaire-9 and Generalised Anxiety Disorder
Assessment-7 to assess depression and anxiety within the
cohort).

The study dataset has been linked to national Pillar 2 test-
ing (PCR and lateral flow testing data through national Test
Trace and Isolate Programme) and the national vaccine regis-
ter as well as hospitalizations and deaths. We have collected
detailed demographic information and clinical comorbidty
data, and have stored serum from participants in the labora-
tory subcohort at two time points, as well as longitudinal se-
rum micro-samples from the vaccine evaluation subcohort.
Virus Watch is one of the few longitudinal studies to present
quantitative spike and nucleocapsid antibody test data among
adults and qualitative (positive/negative) serology among
children, together with detailed vaccination information and
clinical comorbidities.

The cohort has several important limitations. Households self-selected into the study after receiving an
invitation via multiple routes, biasing the sample towards
participants with an interest in COVID-19 and health re-
search. Households with more than six members were not
eligible for the study due to the limitations of the REDCap
survey infrastructure, and people living in institutional set-
tings, such as care homes, university halls of residence and
boarding schools, were not eligible to participate, limiting
the generalizability of findings for these groups.

Retention of participants has decreased significantly
over the 2 years the study has been running. As restrictions
have been lifted and interest in the pandemic has waned
among the general public, around half of the participants
enrolled have stopped regularly completing study surveys.
Participants who have disengaged are more likely to be
younger, from an ethnic minority background and living in
London, limiting statistical power and likely biasing analy-
ses using more recent study data.

Can I get hold of the data? Where can I find
out more?

Given the sensitive content in our dataset (information on
health, income and household characteristics) for this
study, we cannot publish data at the individual level pub-
licly. We are sharing individual record-level data (exclud-
ing any data or variables originating from linkage via NHS
Digital) on the ONS SRS [https://ons.metadata.works/
browser/dataset? id=89201]. The data are available under
restricted access and can be obtained by submitting a
request directly to the SRS. We regularly share results and
updates on the study via a ‘Findings so far’ section on our
website [https://ucl-virus-watch.net/].

Ethics approval

This study has been approved by the Hampstead NHS Health
Research Authority Ethics Committee, Ethics approval number—
20/HRA/2320.

This study uses NHS HES (Admitted Patient Care, Outpatient
Bookings, Emergency Care Dataset and Critical Care), ONS mortal-
ity, Vaccination (NIMS) and COVID-19 testing data (Pillar 2 and
SGSS) which were provided within the terms of a data-sharing
agreement (DARS-NIC-372269-N8D7Z-V1.6) to the researchers by
the Health and Social Care Information Centre (NHS Digital).
The data do not belong to the authors and may not be shared by the
authors, except in aggregate form for publication. Data can be
obtained by submitting a data request through the NHS Digital
Data Access Request Service.

Data availability

See can ‘Can I get hold of the data’ above.

Supplementary data

Supplementary data are available at IJE online.

Author contributions

J.G., R.G., A.R., R.W.A. contributed to the concept and design of
the study; A.H., E.F., J.K., V.N., S.B., T.B., A.A., P.H., L.W.,
W.L.E.F., C.G., P.F., M.Sh., A.M.D.N., E.N., M.Sp., R.W.A. con-
tributed to the overall project administration and coordination;
V.N., W.L.E.F., S.B., A.M.D.N., C.G., T.B., R.W.A. managed and
prepared study data for analysis; J.K., T.B. prepared the manuscript
which was reviewed and edited by all authors.

Funding

This work was supported by the Medical Research Council [Grant
Ref: MC_PC 19070], awarded to UCL on 30 March 2020, and
Medical Research Council [Grant Ref: MR/V028375/1], awarded on
17 August 2020. The study also received $15 000 of advertising credit
from Facebook to support a pilot social media recruitment campaign
on 17 August 2020. The antibody testing undertaken by the vaccine
evaluation subcohort was supported by funding from the Department
of Health and Social Care from February 2021 to March 2022.

From 1 May 2022, Virus Watch received funding from the
European Union (Project: 101046314). Views and opinions
expressed are however those of the author(s) only and do not neces-
sarily reflect those of the European Union or the European Health
and Digital Executive Agency (HaDEA). Neither the European
Union nor the granting authority can be held responsible for them.

This study was supported by the Wellcome Trust through a
Wellcome Clinical Research Career Development Fellowship to
R.W.A. [206602] and a Clinical PhD Fellowship to A.A. [206441/Z/17/Z]. I.B. is supported by an NIHR Academic Clinical Fellowship. S.B. and T.B. are supported by an MRC doctoral studentship (MR/N013867/1). Research at UCL Great Ormond Street Institute of Child Health led by P.H. and L.W. is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre.

Conflict of interest

A.C.H. serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. A.M.J. is Chair of the Committee for Strategic Coordination for Health of the Public Research.

References